Skip to content

Safety and efficacy of Uncross-Matched Type O Red Blood Cell Transfusion to Traumatic hemorrhagic Shock Patients: a National,Multicenter,Prospective study

Safety and efficacy of Uncross-Matched Type O Red Blood Cell Transfusion to Traumatic hemorrhagic Shock Patients: a National,Multicenter,Prospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124779
Enrollment
Unknown
Registered
2026-05-18
Start date
2026-05-19
Completion date
Unknown
Last updated
2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Traumatic hemorrhagic Shock

Interventions

General type O red blood cells / Non-general type O red blood cells observation group:None

Sponsors

Jinling Hosptial affiliated to Nanjing University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age range: 18 - 70 years old; 2. New trauma within 6 hours; 3. Trauma combined with hemorrhagic shock, and the blood consumption score (ABC score) >= 2 points (including 4 indicators: penetrating injury; positive result of trauma ultrasound focused assessment (FAST); systolic blood pressure = 120 beats per minute; each parameter is counted as 1 point); 4. The patient or the authorized representative has signed the informed consent form; 5. The subjects can follow the treatment plan of this study.

Exclusion criteria

Exclusion criteria: 1.Pregnant and lactating women; 2. Patients who have received component blood transfusion within the past three months; 3. Patients with known RhD negativity and a history of anti-D antibody positivity; 4.Patients with severe underlying diseases (e.g., advanced liver cirrhosis, end-stage renal disease, congestive heart failure NYHA class IV, advanced malignancy); 5.Non-traumatic patients, including those with hematological disorders or other indications for component blood transfusion.

Design outcomes

Primary

MeasureTime frame
Total blood transfusion volume within 24 hours;

Secondary

MeasureTime frame
Transfusion reactions: including the incidence of adverse transfusion reactions such as hemolytic reactions and acute renal insufficiency;Blood transfusion time;The total volume of resuscitation fluid within 24 hours;24-hour and 30-day mortality rates; ICU length of stay;

Countries

China

Contacts

Public ContactDing Weiwei

Jinling Hospital affiliated to Nanjing University

dingweiwei@nju.edu.cn+86 25 8086 1671

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026